Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Net Income towards Common Stockholders (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Net Income towards Common Stockholders readings, the most recent being -$17.0 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 65.98% to -$17.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$24.2 million through Mar 2026, up 3.23% year-over-year, with the annual reading at -$17.4 million for FY2025, 34.12% up from the prior year.
  • Net Income towards Common Stockholders hit -$17.0 million in Q1 2026 for Ovid Therapeutics, down from $9.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $9.7 million in Q4 2025 and bottomed at -$17.0 million in Q1 2026.
  • Average Net Income towards Common Stockholders over 5 years is -$9.8 million, with a median of -$12.0 million recorded in 2022.
  • Peak annual rise in Net Income towards Common Stockholders hit 204.43% in 2025, while the deepest fall reached 154.97% in 2025.
  • Ovid Therapeutics' Net Income towards Common Stockholders stood at -$11.5 million in 2022, then plummeted by 33.18% to -$15.3 million in 2023, then skyrocketed by 39.61% to -$9.3 million in 2024, then skyrocketed by 204.43% to $9.7 million in 2025, then crashed by 275.8% to -$17.0 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Net Income towards Common Stockholders are -$17.0 million (Q1 2026), $9.7 million (Q4 2025), and -$12.2 million (Q3 2025).